Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Taiyen Biotech CoTPE:1737 83 Cash Ratio is 1.69 as of Jun. 2026, which is 20% below its 10-year median of 2.12. GuruFocus rates TPE:1737 with a GF Score™ of 83/100 and a GF Value™ of NT$31.13 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,926 Consumer Packaged Goods companies, Taiyen Biotech Co ranks better than 83.49% on this metric.
Taiyen Biotech Co has a Cash Ratio of 1.69. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Taiyen Biotech Co's Cash Ratio or its related term are showing as below:
TPE:1737'
s Cash Ratio Range Over the Past 10 Years
Min: 1.24 Med: 2.12 Max: 5.71
Current: 1.69
During the past 13 years, Taiyen Biotech Co's highest Cash Ratio was 5.71. The lowest was 1.24. And the median was 2.12.
TPE:1737's Cash Ratio is ranked better than 83.49% of 1926
companies
in the Consumer Packaged Goods industry
Industry Median: 0.38
vs TPE:1737: 1.69
Taiyen Biotech Co (TPE:1737) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Taiyen Biotech Co Cash Ratio Related Terms
Taiyen Biotech Co Cash Ratio Historical Data
* Premium members only.
The historical data trend for Taiyen Biotech Co's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Household & Personal Products subindustry, Taiyen Biotech Co's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taiyen Biotech Co Cash Ratio vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Taiyen Biotech Co's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Taiyen Biotech Co's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taiyen Biotech Co (TPE:1737) has a Cash Ratio of 1.69 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Taiyen Biotech Co and its competitors. This is 20% below median its historical median of 2.12. Over the past decade, Taiyen Biotech Co's Cash Ratio has ranged from 1.24 to 5.71. According to the industry distribution chart, Taiyen Biotech Co ranks #318 out of 1926 companies in the Consumer Packaged Goods industry, placing it in the top 16.5%.
Is Taiyen Biotech Co's Cash Ratio too high?
Taiyen Biotech Co's current Cash Ratio of 1.69 is 20% below median its 10-year median of 2.12. Over the past 10 years, this metric has ranged from a low of 1.24 to a high of 5.71. The Consumer Packaged Goods industry median Cash Ratio is 0.38. Taiyen Biotech Co's value of 1.69 is 344.7% above this industry median. Based on the distribution chart, Taiyen Biotech Co ranks #318 out of 1926 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Taiyen Biotech Co has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Taiyen Biotech Co's Cash Ratio compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Taiyen Biotech Co ranks #318 out of 1926 companies for Cash Ratio. This places Taiyen Biotech Co in the top 17% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 0.38. Taiyen Biotech Co's value of 1.69 is 344.7% above this benchmark. Historically, Taiyen Biotech Co's own Cash Ratio has ranged from 1.24 to 5.71 over the past decade. While the company's 10-year median is 2.12 vs. the industry median of 0.38, Taiyen Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Consumer Packaged Goods company?
The median Cash Ratio among Consumer Packaged Goods companies is 0.38, based on 1,926 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Taiyen Biotech Co's current Cash Ratio of 1.69 is 344.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Taiyen Biotech Co and its competitors. For the Consumer Packaged Goods industry, the median Cash Ratio is 0.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taiyen Biotech Co's current Cash Ratio is 1.69, which is 20% below median its own 10-year median of 2.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiyen Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Taiyen Biotech Co (TPE:1737) is currently considered Fairly Valued. The stock's GF Value™ is NT$31.13, compared to a current price of NT$30.70 — trading 1.4% below its estimated fair value. The current Cash Ratio is 1.69, which is 20% below median its 10-year median of 2.12 and 344.7% above the Consumer Packaged Goods industry median of 0.38. Taiyen Biotech Co's overall GF Score™ is 83/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Taiyen Biotech Co (TPE:1737), the current Cash Ratio is 1.69 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taiyen Biotech Co (TPE:1737) Overvalued in 2026?
Based on GuruFocus' analysis, Taiyen Biotech Co stock appears to be undervalued.
The current stock price of NT$30.70 is trading 1.4% below its estimated GF Value™ of NT$31.13.
GuruFocus considers Taiyen Biotech Co to be Fairly Valued.
Key valuation signals for TPE:1737:
Cash Ratio: 1.69 (20% below median its 10-year median of 2.12)
GF Value™: NT$31.13 vs. price of NT$30.70 (1.4% below fair value)
Industry Position: 344.7% above the Consumer Packaged Goods median (#318 of 1926)
No single metric tells the full story. See the TPE:1737 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taiyen Biotech Co Ltd operates in personal care and home care products. Its product portfolio comprises beauty care products, health food, skin products, salt products and spices, bottled water, and medical supplies, among others. The group has four reportable segments; Salt products and packaged water department, Biotech cleaning and maintenance department, Construction and services department, and Other departments.. The Salt and Packaged Product Segment accounts for the bulk of revenue. Geographically it operates through the region of Taiwan; however, it also holds a presence in the international market.
83GF Score
Get the complete analysis for TPE:1737
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1737 has been successfully added to your 
